Alta Partners is a leading venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was formed in 1996 and is based in San Francisco, California.
Join Mergr to view the latest updates and news from San Francisco-based Alta Partners.
Alta Partners’ most common sectors for investment are life science (84%) and medical products (12%). The Firm’s most common investment types include venture (80%) and pipe (9%). In total, Alta Partners has invested in 8 US states and 7 different countries. Its largest (disclosed) acquisition occurred in 2012 when it acquired Bioventus for $118M.
In the last 3 years, Alta Partners has exited 3 companies. The Firm’s most common exit type is trade sale (66%). Alta Partners’ largest (disclosed) exit occurred in 2015 when it sold ZS Pharma for $2.7B.
Join Mergr to view Alta Partners’ full profile and discover more large private equity firms just like it.
Month to month. Cancel anytime.